Company Overview of Merck Research Laboratories
Merck Research Laboratories discovers and develops medicines for cancer and neurodegenerative disorders. The company was founded in 2004 and is based in Boston, Massachusetts. Merck Research Laboratories operates as a subsidiary of Merck & Co. Inc.
33 Avenue Louis Pasteur
Boston, MA 02115
Founded in 2004
Key Executives for Merck Research Laboratories
Senior Vice President and Franchise Head of Immunology Respiratory & Endocrine
Senior Vice President and Franchise Head of Diabetes & Obesity
Senior Vice President and Head of Franchise
Compensation as of Fiscal Year 2014.
Merck Research Laboratories Key Developments
Merck Research Laboratories Presents at ChinaBio Partnering Forum 2015, Apr-15-2015 09:30 AM
Apr 13 15
Merck Research Laboratories Presents at ChinaBio Partnering Forum 2015, Apr-15-2015 09:30 AM. Venue: Kerry Hotel, Pudong, Shanghai, China. Speakers: Yongkui Sun, Scout, Greater China, Business Development and Licensing.
Merck Research Laboratories Presents at 3rd Annual SACHS Cancer Bio Partnering and Investment Forum, Feb-23-2015 08:55 AM
Feb 22 15
Merck Research Laboratories Presents at 3rd Annual SACHS Cancer Bio Partnering and Investment Forum, Feb-23-2015 08:55 AM. Venue: The New York Academy of Sciences, 7 World Trade Center, 250 Greenwich St, 40th Floor (D Elevator Bank), New York, NY10007, United States. Speakers: Ji Li, Vice President, Business Development and Licensing.
BIND Therapeutics, Inc. Announces Agreement with Merck to Develop Targeted Accurin Nanomedicines for Oncology
Nov 6 14
BIND Therapeutics, Inc. announced a joint research and development agreement with Merck, through a subsidiary to discover and develop novel nanomedicines for oncology. This collaboration will leverage BIND's proprietary nanomedicine technology to create targeted Accurins based on novel, potent payloads from Merck's preclinical oncology portfolio. The first two Merck compounds include a kinesin spindle protein (KSP) inhibitor and a polo-like kinase 1 (PLK1) inhibitor. Both KSP and PLK1 are regulators of cellular mitosis and are considered essential to the proliferation of cancer cells. These pathways have proven difficult to target effectively using conventional agents due to therapeutic index limitations. Under the terms of the agreement, BIND will apply its Medicinal Nanoengineering(R) platform to develop targeted Accurins based initially on Merck-supplied investigational KSP and PLK1 inhibitors. The agreement also includes the option to incorporate additional Merck compounds in the future. BIND will fund and conduct research and development activities to advance Accurin product candidates based on these agents through first-in-human clinical studies, after which Merck and BIND will alternate in choosing whether or not to further develop and commercialize the Accurin products. If BIND opts in, in most scenarios there will be no payments made to Merck beyond a royalty on future product sales. If Merck opts in, it will pay BIND a fee based on a multiple of BIND's research and development expenses, plus a royalty on future product sales. Further terms of the agreement were not disclosed.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|